je.st
news
Tag: annual meeting
Canadian Tooling & Machining Association Annual General Meeting & Dinner
2017-07-17 20:16:27| Canadian Plastics Headlines
The CTMA is pleased to announce that it will be holding its Annual General Meeting & Dinner on Wednesday, September 13, 2017 at the Elm Hurst Inn, Ingersoll, Ontario. It promises to be a fantastic event with Keynote Speaker Donald… The post Canadian Tooling & Machining Association Annual General Meeting & Dinner appeared first on Canadian Plastics.
Tags: general
meeting
association
annual
ABBA HOLDS ANNUAL MEMBERSHIP MEETING
2017-06-15 23:26:02| Cattle Today
The American Brahman Breeders Association (ABBA) held its 93rd Annual Membership Meeting March 8 in Houston where they initiated a new president, board members, and officers, and recognized outstanding members of the Brahman breed.
Tags: meeting
annual
membership
holds
IBBA ANNUAL MEETING TO BE HELD FEBRUARY 10-11, 2017
2017-01-16 22:33:23| Cattle Today
The International Brangus Breeders Association's (IBBA) 2017 Annual Meeting & Convention is scheduled for February 10-11 in San Antonio, Texas.
Tags: february
held
meeting
annual
KEYTRUDA (pembrolizumab) Treatment Results in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (cHL) Presented at 58th Annual Meeting of the American Society of Hematology
2016-12-06 01:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data from Pivotal KEYNOTE-087 Trial Show Overall Response Rate (ORR) of 69.0 Percent and Complete Remission Rate (CRR) of 22.4 Percent With More than Two Years of Follow-up, Findings from KEYNOTE-013 Show ORR of 58 Percent and CRR of 19 Percent with Responses of 12 Months or Greater in 70 Percent of Responding Patients KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today updated findings evaluating KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in two trials of patients with relapsed or refractory classical Hodgkin lymphoma (cHL). In the KEYNOTE-087 and KEYNOTE-013 trials, KEYTRUDA demonstrated overall response rates (ORR) of 69.0 percent and 58 percent, respectively. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orKim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: of
results
american
society
Updated KEYTRUDA (pembrolizumab) Findings in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma Presented at 58th Annual Meeting of the American Society of Hematology
2016-12-05 16:42:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. Data from KEYNOTE-013 Demonstrated Overall Response Rate of 41 Percent, with 86 Percent of Responses Ongoing at the Time of Analysis KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today study findings demonstrating that KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, achieved an overall response rate (ORR) of 41 percent (n=7/17) (90% CI, 21-64) with follow-up of up to 27 months in patients with relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), a type of non-Hodgkin lymphoma, who were ineligible for or failed to respond to autologous stem-cell transplantation (ASCT). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Kim Hamilton, 908-740-1863orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE @Merck read more
Tags: of
large
updated
american
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] next »